Download PDF
Aktuelle Rheumatologie 2005; 30(4): 254-265
DOI: 10.1055/s-2005-858569
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Fix-sequenzielle Folsäuresupplementierung bei Methotrexat-Therapie

Fixed Sequential Supplementation with Folic Acid during Methotrexate TherapyW. Miehle1 , C. Tomiak1
  • 1Rehabilitations-Klinik Wendelstein der BfA - Rheumazentrum, Bad Aibling
Further Information

Publication History

Publication Date:
24 August 2005 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Im Abwägen zwischen Folinsäure und Folsäure ergeben sich klare Vorteile für die Folsäure. Diskret höhere MTX-Dosen in den Folsäure-MTX-Gruppen können nötig sein, um die volle MTX-Wirkung zu erhalten, obwohl in der Literatur keine klinisch relevanten Publikationen vorliegen und die Hinweise darauf eher indirekter Natur sind. Es ist aber auch möglich, dass höhere (effektivere) MTX-Dosen erst durch Folsäuregabe realisierbar sind. Die mg-Unterschiede sind zudem marginal (2 bis 4 mg/Woche) und stellen bei gleichzeitiger sicherer Reduzierung der MTX-induzierten unerwünschten Wirkungen einen akzeptablen Kompromiss dar. Ein wöchentliches Folsäure-zu-MTX-Verhältnis von 0,45 : 1,0 bis zu 2,85 : 1,0 reduziert UAW signifikant. Der zeitliche Rahmen, in dem Folsäure im Verhältnis zu MTX gegeben wurde, reichte von 4 Tagen vor bis zu 24 Stunden nach der MTX-Gabe. Folsäure zeigt ein deutlich weiteres „zeitliches Applikationsfenster” als Folinsäure. Folsäure beeinträchtigt unter diesen Dosis- bzw. Zeitverhältnissen die MTX-Wirkung nicht. Folsäure erfüllte die Forderung, unerwünschte Arzneimittelwirkungen zu reduzieren und die MTX-Wirkung nicht zu nivellieren in drei doppelblinden, zwei prospektiven offenen Studien und einer Metaanalyse.

Abstract

When comparing folinic acid with folic acid, clear advantages for folic acid are apparent. Discretely higher doses of MTX may be necessary in the folic acid-MTX group in order to retain the full activity of MTX although no clinically relevant reports are available in the literature and all indications are thus of an indirect nature. However, it is also possible that higher (more effective) doses of MTX may be achievable by means of administration of folic acid. The mg differences are however marginal (2 to 4 mg/week) and - with a concomitant and certain reduction of MTX-induced adverse effects - represent an acceptable compromise. A weekly folic acid to MTX ratio of from 0.45:1.0 up to 2.85:1.0 significantly reduces the adverse events. The time period within which folic acid can be administered in relation to MTX ranges from 4 days before to 24 hours after the administration of MTX. Thus, folic acid exhibits and markedly wider “administration window” than folinic acid. At these doses and timepoints folic acid does not negatively influence the action of MTX. Folic acid has fulfilled the requirements to reduce adverse drug reactions and not to flatten the efficacy of MTX in three double-blind studies, two prospective open studies and a meta-analysis.

Schlüsselwörter

Folsäuresupplementierung - Methotrexat-Therapie - Folinsäure - Folsäure - unerwünschten Wirkungen - zeitliche Applikationsfenster - Folsäure zu MTX-Verhältnis

Key words

Folic acid supplementation - methotrexate therapy - folinic acid - folic acid - adverse events - administration window - folic acid to MTX ratio

Literatur

  • 1 Alarcon G S, Tracy I C, Strand G M. et al . Survival and drug discontinuation analyses in a large cohort of methotrexate-treated rheumatoid arthritis patients.  Ann Rheum Dis. 1995;  54 708-712
    CrossrefPubMedSearch in Google Scholar
  • 2 Alarcon G S. Its use for the treatment of rheumatoid arthritis and other rheumatic disorders. Koopmann WJ Arthritis and allied conditions. A Textbook of rheumatology, 13th Edition Baltimore; Williams & Wilkins 1997: 679-698
    Search in Google Scholar
  • 3 Alarcon G S, Morgan S L. Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate: comment on the guidelines for monitoring drug therapy.  Arthritis Rheum. 1997;  40 (2) 391
    PubMedSearch in Google Scholar
  • 4 Aletaha D, Smolen J S. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses.  Rheumatology. 2002;  41 1367-1374
    CrossrefPubMedSearch in Google Scholar
  • 5 Allegra C J, Drakes J C, Jolivet J. et al . Inhibition of AICAR by methotrexate and dihydrofolic acid polyglutamates.  Proc Natl Acad Sci USA. 1995;  82 4881-4885
    PubMedSearch in Google Scholar
  • 6 American C ollege of Rheumatology AD HOC Committee in Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis.  Arthritis Rheum. 1996;  39 723-731
    PubMedSearch in Google Scholar
  • 7 American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines . Guidelines for the management of rheumatoid arthritis. 2002 Update.  Arthritis Rheum. 2002;  46, 2 328-346
    CrossrefPubMedSearch in Google Scholar
  • 8 Angier R B, Boothe J H, Hutchings B L. Synthesis of a compound identical with the L. casei factor isolated from liver.  Sciene. 1945;  102 227-228
    PubMedSearch in Google Scholar
  • 9 Banks M J, Pace A, Kitas G D. Acute coronary syndromes present atypically and recure more frequently in rheumatoid arthritis than matched controls (abstract).  Arthritis Rheum. 2001;  44 (Suppl) S53
    PubMedSearch in Google Scholar
  • 10 Barankiewicz J, Ronlov G, Jimenez R. et al . Selective adenosine release from human B but not T lymphoid cell line.  J Biol Chem. 1990;  265 15 738-15 743
    PubMedSearch in Google Scholar
  • 11 Barankiewicz J, Jimenez R, Ronlov G. et al . Alteration of purine metabolism by AICA-riboside in human B lymphoblasts.  Arch Biochem Biophys. 1990;  282 377-385
    CrossrefPubMedSearch in Google Scholar
  • 12 Baugh C M, Krumdieck C L, Nair M G. Polygammaglutamyl metabolites of methotrexate.  Biochem Biophys Res C Immun. 1973;  52 27-34
    PubMedSearch in Google Scholar
  • 13 Berthelot J M, Glemarec J, Chiffoleau A. et al . Treatment with low dose methotrexate in rheumatoid arthritis: risk factors for severe complications.  Therapie. 1997;  52 111-116
    PubMedSearch in Google Scholar
  • 14 Boerbooms AMT, Kerstens PJSM, van Loenhout JWA. et al . Infections during low-dose methotrexate treatment in rheumatoid arthritis.  Semin Arthritis Rheum. 1995;  24, 6 411-421
    CrossrefPubMedSearch in Google Scholar
  • 15 Bologna C, Jorgensen C, Sany J. Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients.  Clin Exp Rheumatol. 1997;  15 597-601
    PubMedSearch in Google Scholar
  • 16 Bressolle F, Kinowski J M, Morel J. et al . Folic acid alters methotrexate availability in patients with rheumatoid arthritis.  J Rheumatol. 2000;  27 2110-2114
    PubMedSearch in Google Scholar
  • 17 Brick J E, Moreland L W, Al-Kawas F. Prospective analysis liver biopsies before and after methotrexate therapy in rheumatoid arthritis.  Semin Arthritis Rheum. 1989;  19 31-44
    CrossrefPubMedSearch in Google Scholar
  • 18 British National Formulary 45. London; BMA. RPS 2003
    Search in Google Scholar
  • 19 British Society for Rheumatology .National guidelines for the monitoring of second line drugs. London; 2000
    Search in Google Scholar
  • 20 Buckley L M, Vacek P M, Cooper S M. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis.  J Rheumatol. 1990;  17 1158-1161
    PubMedSearch in Google Scholar
  • 21 Cronstein B N, Hirschorn R. Adenosine and host defence: Modulation through metabolism and receptor-mediated mechanisms. Williams M Adenosine and adenosine receptors Clifton, NJ; The Humana Press 1990: 475-500
    Search in Google Scholar
  • 22 Cronstein B N, Eberle M A, Gruer H E. et al . Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells.  Proc Natl Acad Sci USA. 1991;  88 2441-2445
    PubMedSearch in Google Scholar
  • 23 Cronstein B N, Naime D, Ostad E. The inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.  J Clin Invest. 1993;  92 2675-2682
    PubMedSearch in Google Scholar
  • 24 Cronstein B N. The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism.  Br J Rheumatol. 1995;  34 (Suppl 2) 30-32
    PubMedSearch in Google Scholar
  • 25 Cronstein B N. Molecular therapeutics. Methotrexate and its mechanisms of action.  Arthritis Rheum. 1996;  39, 12 1951-1960
    PubMedSearch in Google Scholar
  • 26 Deeming G MJ, Collingwood J, Pemberton M N. Methotrexate and oral ulceration.  Br Dent J. 2005;  198 (2) 83-85
    CrossrefPubMedSearch in Google Scholar
  • 27 Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis.  J Am Acad Dermatol. 1993;  28, 3 466-469
    PubMedSearch in Google Scholar
  • 28 Emery P, Breedveld F C, Lemmel E M. et al . A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.  Rheumatology. 2000;  39 655-665
    CrossrefPubMedSearch in Google Scholar
  • 29 Endresen G K, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines.  Scand J Rheumatol. 2001;  30 129-134
    CrossrefPubMedSearch in Google Scholar
  • 30 Griffith S M, Fisher J, Clarke S. et al . Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?.  Rheumatology. 2000;  39 1102-1109
    CrossrefPubMedSearch in Google Scholar
  • 31 Groff G D, Shenberger K N, Wilke W S. et al . Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature.  Semin Arthritis Rheum. 1983;  12 (4) 333-347
    CrossrefPubMedSearch in Google Scholar
  • 32 Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II Effect oft aminopterin in rheumatoid arthritis and psoriasis.  Am J Med Sci. 1951;  221 176-182
    PubMedSearch in Google Scholar
  • 33 Gulko P S, Tracy I C, Baum S K. et al . Practice pattern in the use of supplemental folic acid in rheumatoid arthritis patients treated with methotrexate.  Rev Brasil Rheumatol. 1994;  34 238
    PubMedSearch in Google Scholar
  • 34 Haagsma C J. Combination of sulphasalazine and methotrexate in the treatment of rheumatoid arthritis. Doctoral thesis. Nijmegen, Netherlands; University of Nijmegen, The Netherlands 1997
    Search in Google Scholar
  • 35 Haagsma C J, Blom H J, van Riel P LCM. et al . Influence of sulphasalazine, methotrexate, and the combination of both on plasma homcysteine concentrations in patients with rheumatoid arthritis.  Ann Rheum Dis. 1999;  58 79-84
    PubMedSearch in Google Scholar
  • 36 Halevy S, Giryes H, Avinoach I. et al . Leukocytoclastic vasculitis induced by low-dose methotrexate: in vitro evidence for an immunologic mechanism.  J Euro Acad Dermatol Venereol. 1998;  10 81-85
    PubMedSearch in Google Scholar
  • 37 Hanrahan P S, Russell A S. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis.  J Rheumatol. 1988;  15 1078-1080
    PubMedSearch in Google Scholar
  • 38 Harten P. Folsäure zur Reduktion der Methotrexat-Toxizität.  Z Rheumatol. 2005;  64 353-358
    CrossrefPubMedSearch in Google Scholar
  • 39 Hoekstra M, van de Laar MAFJ, Moens HJB. et al . Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.  J Rheumatol. 2003;  30 2325-2329
    PubMedSearch in Google Scholar
  • 40 Hoekstra M, van Ede A E, Haagsma C J. et al . Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis.  Ann Rheum Dis. 2003;  62 423-426
    CrossrefPubMedSearch in Google Scholar
  • 41 Hoekstra M, Haagsma C J, Doelman C JA. et al . Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate.  Ann Rheum Dis. 2005;  64 141-143
    CrossrefPubMedSearch in Google Scholar
  • 42 Hoffmeister R T. Methotrexate therapy in rheumatoid arthritis: 15 years experience.  Am J Med. 1983;  75 69-73
    CrossrefPubMedSearch in Google Scholar
  • 43 Hunt R E, Phillips R M, Shergy W J. Role of folic acid in limiting methotrexate related side effects.  Arthritis Rheum. 1994; 37 (Suppl) S253
    PubMed
  • 44 Hunt P G, Rose C D, McIlvain-Simpson G. et al . The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study.  J Rheumatol. 1997;  224 (11) 2230-2232
    PubMedSearch in Google Scholar
  • 45 Ince A, Yazici Y, Hamuryudan V. et al . The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): A masked and controlled study.  Clin Rheumatol. 1996;  15 491-494
    PubMedSearch in Google Scholar
  • 46 Jacobs S A, Derr C J, Johns D G. Accumulation of methotrexate diglutamate in human liver during methotrexate therapy.  Biochem Pharmacol. 1977;  26 2310-2313
    CrossrefPubMedSearch in Google Scholar
  • 47 Jensen O K, Rasmussen C, Mollerup F. et al . Hyperhomocysteinemia in rheumatoid arthritis: Influence of methotrexate treatment and folic acid supplementation.  Rheumatol. 2002;  29 1615-1618
    PubMedSearch in Google Scholar
  • 48 Jeurissen M EC, Boerbooms A MT, van de Putte L BA. Eruption of nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis.  Clin Rheumatol. 1989;  8 417-418
    CrossrefPubMedSearch in Google Scholar
  • 49 Jobanputra P, Hunter M, Clark D. et al . An audit of methotrexate and folic acid for rheumatoid arthritis: experience from a teaching centre.  Br J Rheumatol. 1995;  34 971-975
    PubMedSearch in Google Scholar
  • 50 Joyce D A, Will R K, Hoffmann D M. et al . Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.  Ann Rheum Dis. 1991;  50 913-914
    PubMedSearch in Google Scholar
  • 51 Kent P D, Luthra H S, Michet C Jr. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.  J Rheumatol. 2004;  31 (9) 1727-1731
    PubMedSearch in Google Scholar
  • 52 Kremer J M, Lee R G, Tolman K G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples.  Arthritis Rheum. 1989;  32 121-127
    CrossrefPubMedSearch in Google Scholar
  • 53 Kremer J M, Phelps C T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months.  Arthritis Rheum. 1992;  35 138-145
    CrossrefPubMedSearch in Google Scholar
  • 54 Kremer J M, Petrillo G F, Hamilton R A. The effects of nonsteroidal anti-inflammatory drugs on methotrexate pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg.  J Rheumatol. 1995;  22 2072-2077
    PubMedSearch in Google Scholar
  • 55 Kremer J M. Toward a better understanding of methotrexate.  Arthritis Rheum. 2004;  50 1370-1382
    CrossrefPubMedSearch in Google Scholar
  • 56 Kommission Qualitätssicherung der Deutschen Gesellschaft für Rheumatologie(2000) Methotrexat. Qualitätssicherung in der Rheumatologie Darmstadt; Verlag Steinkopff 5.3.7.1-5.3.7.3
  • 57 Lorenzi A R, Johnson A H, Gough. Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and voimiting and avoids the need for antiemetic prescription.  Rheumatology. 2000;  39 812-813
    CrossrefPubMedSearch in Google Scholar
  • 58 Maetzel A, Wong A, Strand V. et al . Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs.  Rheumatology. 2000;  39 975-891
    CrossrefPubMedSearch in Google Scholar
  • 59 Manzi S, Wanko, MCM. Inflammation-mediated rheumatic disease and atherosclerosis (Leader).  Ann Rheum Dis. 2000;  59 321-325
    CrossrefPubMedSearch in Google Scholar
  • 60 Maradit-Kremers H, Crowson C S, Nicola P J. et al . Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.  Arthritis Rheum. 2005;  52 (2) 402-411
    CrossrefPubMedSearch in Google Scholar
  • 61 McKendry R JR. The remarkable spectrum of methotrexate toxicities.  Rheum Dis Clin N Am. 1997;  23 939-955
    PubMedSearch in Google Scholar
  • 62 Michaels R M, Nashel D J, Leonard A. et al . Weekly intravenous methotrexate in the treatment of rheumatoid arthritis.  Arthritis Rheum. 1982;  25, 3 339-341
    PubMedSearch in Google Scholar
  • 63 Mitchell H, Snell E, Williams R. The concentration of „folic acid”.  J Am Chem Soc. 1941;  63 2284
    PubMedSearch in Google Scholar
  • 64 Montesinos M C, Desai A, Delano D. et al . Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68.  Arthritis Rheum. 2003;  48 (1) 240-247
    CrossrefPubMedSearch in Google Scholar
  • 65 Morgan S L, Baggott J E, Vaughn W H. et al . The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.  Arthritis Rheum. 1990;  33 9-18
    CrossrefPubMedSearch in Google Scholar
  • 66 Morgan S L, Baggott J E, Vaughn W H. et al . 5 mg or 50 mg/week of folic acid (FA) supplementation does not alter the efficacy of methotrexate (MTX) treated rheumatoid arthritis (RA) patients.  Arthritis Rheum. 1992;  35 (Suppl 9) (abstract) R18
    PubMedSearch in Google Scholar
  • 67 Morgan S L, Baggott J B, Vaughn W H. et al . Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial.  Ann Intern Med. 1994;  121 833-841
    PubMedSearch in Google Scholar
  • 68 Morgan S L, Oster R A, Lee J Y. et al . The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis.  Arthritis Rheum. 2004;  50 (10) 3104-3111
    CrossrefPubMedSearch in Google Scholar
  • 69 Moritz F, Wagner U, Distler O. et al . Kardiovaskuläre Manifestationen bei Rheumatoider Arthritis.  Z Rheumatol. 2005;  64 222-228
    CrossrefPubMedSearch in Google Scholar
  • 70 Ortiz Z, Shea B, Suarez-Almazor M. et al . The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.  J Rheumatol. 1998;  25 36-43
    PubMedSearch in Google Scholar
  • 71 Parmely M J, Zhou W W, Edwards III CK. et al . Adenosine and a related carbocyclic nucleeoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge.  J Immunol. 1993;  151 389-396
    PubMedSearch in Google Scholar
  • 72 Rau R, Schleusser B, Herborn G. et al . Longterm treatment of destructive rheumatoid arthritis with methotrexate.  J Rheumatol. 1997;  24 1881-1889
    PubMedSearch in Google Scholar
  • 73 Rau R. Langzeittherapie der chronischen Polyarthritis mit Methotrexat. Rau R Chronische Polyarthritis - Therapie mit Methotrexat München; Futuramed Verlag 1992: 19-34
    Search in Google Scholar
  • 74 Rosenblatt D S, Whitehead V M, Vera N. et al . Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells.  Mol Pharmacol. 1978;  14 1143-1147
    PubMedSearch in Google Scholar
  • 75 Salaffi F, Carotti M, Sartini A. et al . A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis.  Clin Exp Rheumatol. 1995;  13 23-28
    PubMedSearch in Google Scholar
  • 76 Schiff M H. Leflunomide versus methotrexate: a comparison of the European and American experience.  Scand J Rheumatol. 1999;  28 (Suppl 112) 31-35
    PubMedSearch in Google Scholar
  • 77 Schnabel A, Gross W L. Low-dose methotrexate in rheumatic diseases. Efficacy, side effects, and risk factors for side effects.  Semin Arthritis Rheum. 1994;  23 310-327
    CrossrefPubMedSearch in Google Scholar
  • 78 Schroder H. Methotrexate pharmacokinetics in age-fractional erythrocytes.  Cancer Chemother Pharm. 1986;  28 203-207
    PubMedSearch in Google Scholar
  • 79 Shiroky J B, Neville C, Esdaile J M. et al . Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 1993;  36 795-803
    PubMedSearch in Google Scholar
  • 80 Shiroky J B. The use of folates concomitantly with low-dose pulse methotrexate.  Rheum Dis Clin North Am. 1997;  23 969-980
    CrossrefPubMedSearch in Google Scholar
  • 81 Speletas M, Papadopoulos N, Daiou C. et al . Relationship between 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and methotrexate-related toxicity in patients with autoimmune diseases receiving folic acid supplementation.  Ann Rheum Dis. 2005;  64 (Suppl III) 421
    PubMedSearch in Google Scholar
  • 82 Stampfer M J, Malinow R, Willett W C. et al . A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.  JAMA. 1992;  268 877-881
    CrossrefPubMedSearch in Google Scholar
  • 83 Steinsson K, Weinstein A, Korn J. et al . Low dose methotrexate in rheumatoid arthritis.  J Rheumatol. 1982;  9 (6) 860-866
    PubMedSearch in Google Scholar
  • 84 Stewart K A, Mackenzie A H, Clough J D. et al . Folate supplementation in methotrexate-treated rheumatoid arthritis patients.  Semin Arthritis Rheum. 1991;  20 (5) 332-338
    CrossrefPubMedSearch in Google Scholar
  • 85 Stone J, Doube A, Dudson D. et al . Inadequate calcium, folic acid, vitamin E, zinc, and selenium intake in rheumatoid arthritis patients: results of a dietary survey.  Semin Arthritis Rheum. 1997;  27 (3) 180-185
    CrossrefPubMedSearch in Google Scholar
  • 86 Strand V, Cohen S, Schiff M. et al . Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomid Rheumatoid Arthritis Investigators Gorup.  Arch Intern Med. 1999;  159 2542-2550
    CrossrefPubMedSearch in Google Scholar
  • 87 Tanaka Y, Shiozawa K, Nishibayashi Y. et al . Methotrexate induced early onset pancytopenia in rheumatoid arthritis: Drug allergy! Idiosyncrasy?.  J Rheumatol. 1992;  19 1320-1321
    PubMedSearch in Google Scholar
  • 88 Tett S E, Triggs E J. Use of methotrexate in older patients. A risk-benefit assessment.  Drugs Aging. 1996;  9 458-471
    PubMedSearch in Google Scholar
  • 89 Tishler M, Caspi D, Fishel B. et al . The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients.  Arthritis Rheum. 1988;  31 906-908
    PubMedSearch in Google Scholar
  • 90 van Ede A E, Laan R F, Rood M J. et al . Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter randomized, double-blind, placebo-controlled study.  Arthritis Rheum. 2001;  44 1515-1524
    CrossrefPubMedSearch in Google Scholar
  • 91 van Ede A E, Laan R F, Blom H J. et al . The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.  Arthritis Rheum. 2001;  44 2525-2530
    CrossrefPubMedSearch in Google Scholar
  • 92 van Ede A E, Laan R F, Blom J H. et al . Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.  Rheumatology. 2002;  41 658-665
    CrossrefPubMedSearch in Google Scholar
  • 93 Weinblatt M E, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy.  Arthritis Rheum. 1989;  32 1592-1596
    PubMedSearch in Google Scholar
  • 94 Weinblatt M E, Maier A L, Coblyn J S. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial.  J Rheumatol. 1993;  20 950-952
    PubMedSearch in Google Scholar
  • 95 Whittle S L, Hughes R A. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.  Rheumatology. 2004;  43 267-271
    PubMedSearch in Google Scholar
  • 96 Wilke W S, Mackenzie A H, Scherbel A L. et al . Toxicity from methotrexate may be dose related.  Arthritis Rheum. 1983;  26, 1 119-120
    PubMedSearch in Google Scholar
  • 97 Wilke W S, Makenzie A H. Methotrexate therapy in rheumatoid arthritis current status.  Drugs. 1986;  33 113
    PubMedSearch in Google Scholar
  • 98 Williams H J, Willkens R F, Samuelson C O Jr. et al . Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.  Arthritis Rheum. 1985;  28 (7) 721-730
    PubMedSearch in Google Scholar
  • 99 Wluka A, Buchbinder R, Mylvaganam A. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.  J Rheumatol. 2000;  27 1864-1871
    PubMedSearch in Google Scholar
  • 100 Wolfe F, Hawley D J, Pincus T. Methotrexate alters the course of rheumatoid arthritis (RA). Increased survival of methotrexate-treated RA-patients: a 25-year study of 1842 patients.  Arthritis Rheum. 1998;  9 (suppl) 188
    PubMedSearch in Google Scholar

Dr. med. Wolfgang Miehle

Internist - Rheumatologe, Leitender Arzt der Rehabilitations-Klinik Wendelstein der BfA - Rheumazentrum

Kolbermoorer Straße 56

83043 Bad Aibling

Email: klinik-wendelstein@t-online.de